Aviceda aims to raise $200M; Nerviano gets back rights to PARP1 inhibitor

In the latest news, Avice­da Therapeutics, a biotech company based in Boston, is looking to raise $200 million in financing. This move signals their commitment to advancing their research and development efforts.

Additionally, Ner­viano has regained the rights to a PARP1 inhibitor, adding a valuable asset back to their portfolio. This strategic decision positions them well for future developments in the field.

It’s also worth noting that there have been updates from Maat Pharma, Secretome Therapeutics, 35Pharma, MediGene, and Doron Therapeutics. These companies continue to make waves in the biotech industry with their innovative approaches and groundbreaking discoveries.

Overall, the biotech sector is buzzing with activity, and these recent developments are just a glimpse of the exciting advancements happening in the field. Stay tuned for more updates as these companies work towards shaping the future of healthcare.